Does the media refer more to CYTK or ALNY?

In the previous week, Cytokinetics had 5 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 12 mentions for Cytokinetics and 7 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.19 beat Cytokinetics' score of -0.05 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Alnylam Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, BIIB or CYTK?

Biogen has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.29 $1.29B $5.65 39.02 Cytokinetics $88.04M 91.42 -$784.96M -$7.22 N/A

Is BIIB or CYTK more profitable?

Biogen has a net margin of 8.32% compared to Cytokinetics' net margin of -1,321.12%. Biogen's return on equity of 11.18% beat Cytokinetics' return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Cytokinetics -1,321.12% N/A -51.01%

Does the media favor BIIB or CYTK?

In the previous week, Cytokinetics had 4 more articles in the media than Biogen. MarketBeat recorded 12 mentions for Cytokinetics and 8 mentions for Biogen. Biogen's average media sentiment score of 1.02 beat Cytokinetics' score of -0.05 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor CYTK or ROIV?

In the previous week, Cytokinetics had 9 more articles in the media than Roivant Sciences. MarketBeat recorded 12 mentions for Cytokinetics and 3 mentions for Roivant Sciences. Cytokinetics' average media sentiment score of -0.05 beat Roivant Sciences' score of -0.54 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Roivant Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative

Is INSM or CYTK more profitable?

Insmed has a net margin of -76.94% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% Cytokinetics -1,321.12% N/A -51.01%

Does the media favor INSM or CYTK?

In the previous week, Cytokinetics had 7 more articles in the media than Insmed. MarketBeat recorded 12 mentions for Cytokinetics and 5 mentions for Insmed. Insmed's average media sentiment score of 0.59 beat Cytokinetics' score of -0.05 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, CYTK or INCY?

Incyte has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytokinetics $88.04M 91.42 -$784.96M -$7.22 N/A Incyte $5.14B 4.57 $1.29B $7.85 14.75

Is CYTK or INCY more profitable?

Incyte has a net margin of 27.71% compared to Cytokinetics' net margin of -1,321.12%. Incyte's return on equity of 29.93% beat Cytokinetics' return on equity. Company Net Margins Return on Equity Return on Assets Cytokinetics -1,321.12% N/A -51.01% Incyte 27.71% 29.93% 22.88%

Does the media favor CYTK or INCY?

In the previous week, Incyte had 11 more articles in the media than Cytokinetics. MarketBeat recorded 23 mentions for Incyte and 12 mentions for Cytokinetics. Incyte's average media sentiment score of 0.62 beat Cytokinetics' score of -0.05 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Incyte 7 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cytokinetics (CYTK) Competitors

$65.60 -0.02 (-0.03%)

Closing price 04:00 PM Eastern

Extended Trading

$64.98 -0.61 (-0.94%)

As of 05:07 PM Eastern

Compare

CYTK vs. ALNY, BIIB, ROIV, INSM, and INCY

Should you buy Cytokinetics stock or one of its competitors? Cytokinetics's main competitors and comparable companies include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Roivant Sciences (ROIV), Insmed (INSM), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cytokinetics compare to Alnylam Pharmaceuticals?

Cytokinetics (NASDAQ:CYTK) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

In the previous week, Cytokinetics had 5 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 12 mentions for Cytokinetics and 7 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.19 beat Cytokinetics' score of -0.05 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Alnylam Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Alnylam Pharmaceuticals has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	91.42	-$784.96M	-$7.22	N/A
Alnylam Pharmaceuticals	$3.71B	8.00	$313.75M	$5.38	41.28

Cytokinetics has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Cytokinetics' net margin of -1,321.12%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Cytokinetics presently has a consensus price target of $106.00, suggesting a potential upside of 63.87%. Alnylam Pharmaceuticals has a consensus price target of $366.90, suggesting a potential upside of 65.20%. Given Alnylam Pharmaceuticals' higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

Summary

Alnylam Pharmaceuticals beats Cytokinetics on 11 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to Biogen?

Biogen (NASDAQ:BIIB) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

Biogen has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.29	$1.29B	$5.65	39.02
Cytokinetics	$88.04M	91.42	-$784.96M	-$7.22	N/A

Biogen presently has a consensus price target of $230.14, suggesting a potential upside of 4.39%. Cytokinetics has a consensus price target of $106.00, suggesting a potential upside of 63.87%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts plainly believe Cytokinetics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85

Biogen has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

87.9% of Biogen shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 2.6% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Cytokinetics had 4 more articles in the media than Biogen. MarketBeat recorded 12 mentions for Cytokinetics and 8 mentions for Biogen. Biogen's average media sentiment score of 1.02 beat Cytokinetics' score of -0.05 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Biogen has a net margin of 8.32% compared to Cytokinetics' net margin of -1,321.12%. Biogen's return on equity of 11.18% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Cytokinetics	-1,321.12%	N/A	-51.01%

Summary

Biogen beats Cytokinetics on 10 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to Roivant Sciences?

Cytokinetics (NASDAQ:CYTK) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Roivant Sciences has lower revenue, but higher earnings than Cytokinetics. Roivant Sciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	91.42	-$784.96M	-$7.22	N/A
Roivant Sciences	$8.26M	3,102.65	-$299.77M	-$0.53	N/A

Cytokinetics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

Cytokinetics has a net margin of -1,321.12% compared to Roivant Sciences' net margin of -3,534.96%. Cytokinetics' return on equity of 0.00% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

64.8% of Roivant Sciences shares are held by institutional investors. 2.6% of Cytokinetics shares are held by insiders. Comparatively, 8.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Cytokinetics had 9 more articles in the media than Roivant Sciences. MarketBeat recorded 12 mentions for Cytokinetics and 3 mentions for Roivant Sciences. Cytokinetics' average media sentiment score of -0.05 beat Roivant Sciences' score of -0.54 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Roivant Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

Cytokinetics presently has a consensus target price of $106.00, indicating a potential upside of 63.87%. Roivant Sciences has a consensus target price of $45.64, indicating a potential upside of 28.63%. Given Cytokinetics' stronger consensus rating and higher possible upside, research analysts clearly believe Cytokinetics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Summary

Cytokinetics beats Roivant Sciences on 9 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to Insmed?

Insmed (NASDAQ:INSM) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

Insmed has a net margin of -76.94% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Cytokinetics	-1,321.12%	N/A	-51.01%

Cytokinetics has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	38.97	-$1.28B	-$4.11	N/A
Cytokinetics	$88.04M	91.42	-$784.96M	-$7.22	N/A

In the previous week, Cytokinetics had 7 more articles in the media than Insmed. MarketBeat recorded 12 mentions for Cytokinetics and 5 mentions for Insmed. Insmed's average media sentiment score of 0.59 beat Cytokinetics' score of -0.05 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Insmed has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

Insmed currently has a consensus target price of $200.57, suggesting a potential upside of 85.33%. Cytokinetics has a consensus target price of $106.00, suggesting a potential upside of 63.87%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

Insmed beats Cytokinetics on 10 of the 15 factors compared between the two stocks.

How does Cytokinetics compare to Incyte?

Cytokinetics (NASDAQ:CYTK) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Cytokinetics presently has a consensus price target of $106.00, indicating a potential upside of 63.87%. Incyte has a consensus price target of $126.15, indicating a potential upside of 8.93%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85
Incyte	0 Sell rating(s)	12 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.56

97.0% of Incyte shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by company insiders. Comparatively, 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Incyte had 11 more articles in the media than Cytokinetics. MarketBeat recorded 23 mentions for Incyte and 12 mentions for Cytokinetics. Incyte's average media sentiment score of 0.62 beat Cytokinetics' score of -0.05 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Incyte	7 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	91.42	-$784.96M	-$7.22	N/A
Incyte	$5.14B	4.57	$1.29B	$7.85	14.75

Cytokinetics has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, Incyte has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Incyte has a net margin of 27.71% compared to Cytokinetics' net margin of -1,321.12%. Incyte's return on equity of 29.93% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
Incyte	27.71%	29.93%	22.88%

Summary

Incyte beats Cytokinetics on 13 of the 17 factors compared between the two stocks.

Get Cytokinetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYTK vs. The Competition

Export

Metric	Cytokinetics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.16B	$3.84B	$7.10B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-9.09	12.99	274.61	26.05
Price / Sales	92.71	1,288.54	601.02	89.39
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	-12.17	16.63	10.92	6.31
Net Income	-$784.96M	-$22.67M	$3.50B	$361.43M
7 Day Performance	1.45%	-3.06%	-2.11%	-1.67%
1 Month Performance	-8.80%	-10.76%	-6.34%	-3.94%
1 Year Performance	16.48%	21.10%	8.81%	2.77%

Cytokinetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYTK Cytokinetics	2.1543 of 5 stars	$65.60 0.0%	$106.00 +61.6%	+17.5%	$8.16B	$88.04M	N/A	673
ALNY Alnylam Pharmaceuticals	3.9166 of 5 stars	$244.32 +2.0%	$367.20 +50.3%	-49.8%	$32.06B	$3.71B	45.41	2,770	Analyst Forecast
BIIB Biogen	3.0438 of 5 stars	$219.07 +1.7%	$230.14 +5.1%	+44.5%	$31.84B	$9.89B	38.77	7,500	Trending News
ROIV Roivant Sciences	2.6295 of 5 stars	$38.99 -2.0%	$45.64 +17.0%	+125.4%	$28.73B	$8.26M	N/A	721
INSM Insmed	3.4508 of 5 stars	$121.00 +0.8%	$204.91 +69.3%	-26.3%	$26.21B	$606.42M	N/A	1,664	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYTK) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytokinetics (CYTK) Competitors

CYTK vs. ALNY, BIIB, ROIV, INSM, and INCY

How does Cytokinetics compare to Alnylam Pharmaceuticals?

Summary

How does Cytokinetics compare to Biogen?

Summary

How does Cytokinetics compare to Roivant Sciences?

Summary

How does Cytokinetics compare to Insmed?

Summary

How does Cytokinetics compare to Incyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK vs. The Competition

Cytokinetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytokinetics (CYTK) Competitors

CYTK vs. ALNY, BIIB, ROIV, INSM, and INCY

How does Cytokinetics compare to Alnylam Pharmaceuticals?

Does the media refer more to CYTK or ALNY?

Do insiders and institutionals hold more shares of CYTK or ALNY?

Which has higher earnings & valuation, CYTK or ALNY?

Which has more risk and volatility, CYTK or ALNY?

Is CYTK or ALNY more profitable?

Do analysts recommend CYTK or ALNY?

Summary

How does Cytokinetics compare to Biogen?

Which has better valuation & earnings, BIIB or CYTK?

Do analysts prefer BIIB or CYTK?

Which has more volatility and risk, BIIB or CYTK?

Do institutionals and insiders have more ownership in BIIB or CYTK?

Does the media favor BIIB or CYTK?

Is BIIB or CYTK more profitable?

Summary

How does Cytokinetics compare to Roivant Sciences?

Which has better earnings & valuation, CYTK or ROIV?

Which has more risk and volatility, CYTK or ROIV?

Is CYTK or ROIV more profitable?

Do institutionals & insiders believe in CYTK or ROIV?

Does the media favor CYTK or ROIV?

Do analysts prefer CYTK or ROIV?

Summary

How does Cytokinetics compare to Insmed?

Is INSM or CYTK more profitable?

Which has better earnings & valuation, INSM or CYTK?

Does the media favor INSM or CYTK?

Which has more volatility & risk, INSM or CYTK?

Do analysts recommend INSM or CYTK?

Summary

How does Cytokinetics compare to Incyte?

Do analysts rate CYTK or INCY?

Do institutionals and insiders have more ownership in CYTK or INCY?

Does the media favor CYTK or INCY?

Which has stronger earnings and valuation, CYTK or INCY?

Which has more volatility and risk, CYTK or INCY?

Is CYTK or INCY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK vs. The Competition

Cytokinetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools